Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors ('statins') in familial combined hyperlipidemia

American Journal of Cardiology

Volumn 81, Issue 4 A, 1998, Pages 43B-46B

  Schonfeld, Gustav ^a   Aguilar Salina, Carlos ^a   Elias, Nizar ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CHROMOSOME 11; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG EFFICACY; FAMILIAL HYPERLIPEMIA; GENETIC LINKAGE; HUMAN; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL;

EID: 0032568086     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00037-X     Document Type: Conference Paper

References (49)

1. Goldstein JL, Schrott HG, Hazarrd WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease, II: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, familial combined hyperlipidemia. J Clin Invest 1973;52:1544-1568.
2. Grundy SM, Chait A, Brunzell JD. Familial combined hyperlipidemia workshop. Arteriosclerosis 1987;7:203-207.
3. Kissebah AH, Alfarsi S, Adams PW. Integrated regulation of very low density lipoprotein triglycerides and apolipoprotein B kinetics in man: normolipidemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. Metabolism 1981;30:856-868.
4. Cortner JA, Coates PM, Bennett MJ, Cryer DR, Le NA. Familial combined hyperlipidemia: use of stable isotopes to demonstrate overproduction of very low density lipoprotein apolipoprotein B by the liver. J Inher Metab Dis 1991;14: 915-922.
5. Venkatesan S, Cullen P, Pacy P, Halliday D, Scott J. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb 1993;13:1110-1118.
6. Austin MA, Brunzell JD, Fitch WL, Krauss RM. Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. Arteriosclerosis 1990;10:520-530.
7. Chait A, Brazg RL, Krauss RM. Susceptibility of small, dense, low density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993;94:350-356.
8. Hunt SC, Wu LL, Hopkins PN, Stults BM, Kuida H, Ramirez ME, Lalouel JM, Williams RR. Apolipoprotein, low density lipoprotein subfraction and insulin resistance with familial combined hyperlipidemia: study of Utah patients with familial dyslipidemic hypertension. Arteriosclerosis 1989;9:335-344.
9. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apoCIII gene expression in transgenic mice. Science 1990;249:790-793.
10. Aalto-Setala K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL. Mechanisms of hypertriglyceridemia in human apolipoprotein CIII transgenic mice. J Clin Invest 1992; 90:1889-1900.
11. Hayek T, Azrolan N, Vardy RB, Walsh A, Chajek-Shaul T, Agellon LB, Tall AR, Breslow JL. Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein level, particle sizes, and metabolism: studies in transgenic mice. J Clin Invest 1993;92:1143-1152.
12. Rauh G, Schuster H, Muller B, Schewe S, Keller C, Wolfram G, Zollner N. Genetic evidence from seven families that the apolipoprotein B gene is not involved in familial combined hyperlipidemia. Atherosclerosis 1990;83:81-87.
13. Aguilar-Salinas CA, Barrett PHR, Pulai J, Zhu XL, Schonfeld G. A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism: kinetics of apolipoprotein B during placebo and pravastatin therapy. Arterioscler Thromb Vasc Biol 1997;17:72-82.
14. Tybjaerg-Hansen A, Nordestgaard BG, Gerdes LU, Faergeman O, Humphries SE. Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis. Atherosclerosis 1993;100:157-169.
15. Dallinga-Thie GM, Van Linde-Sibenius Trip M, Rotter JI, Cantor RM, Bu XD, Lusis AJ, De Bruin TWA. Complex genetic contribution of the apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. J Clin Invest 1997;99: 953-961.
16. Babirak SP, Brown BG, Brunzell JD. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler Thromb 1992;12:1176-1183.
17. Castro Cabezas M, De Bruin TWA, De Valk HW, Shoulders CC, Jansen H, Erkelens W. Impaired fatty acid metabolism in familial combined hyperlipidemia: a mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest 1993;92:160-168.
18. Chen M, Breslow JL, Left T. Transcriptional regulation of the apoCIII gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res 1994;35:1918-1924.
19. Krauss RM, Herbert PM, Levy RI, Fredrickson DS. Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins. Circ Res 1973;33:403-411.
20. Windler E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res 1985;26:556-565.
21. Brunzell JD, Albers JJ, Chait A, Grundy SM. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983;24:147-155.
22. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-1389.
23. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, McFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
24. Frick MH, Elo OE, Happa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-1245.
25. Vega GL, Grundy SM. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. JAMA 1985;253:2398-2403.
26. Napoli C, Lepore S, Condorelli M, Chiariello M. Long-term treatment with simvastatin in patients with familial combined hyperlipidemia. Curr Ther Res 1995;56:70-80.
27. Vega GL, Grundy SM. Management of primary mixed hyperlipidemia with lovastatin. Arch Intern Med 1990;150:1313-1319.
28. Mostaza JM, Schulz I, Vega GL, Grundy SM. Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia. Am J Cardiol 1997;79:1298-1301.
29. Bruckert E, De Gennes JL, Malbecq W, Baigts F. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. Clin Cardiol 1995;18:621-629.
30. Ojala JP, Helve E, Tikkanen MJ. Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil: a comparison study. Cardiology 1990;77(suppl 4):39-49.
31. Nestel P, Simons L, Barter P, Clifton P, Colquhoun D, Hamilton-Craig I, Sikaris K, Sullivan D. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. Atherosclerosis 1997;129: 231-239.
32. Zambon S, Cortella A, Sartore G, Baldo-Enzi G, Manzato E, Crepaldi G. Pravastatin treatment in combined hyperlipidemia: effect on plasma lipoprotein level and size. Eur J Clin Pharmacol 1994;46:221-224.
33. Lea AP, McTavish D. Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidemias. Drugs 1997;53:828-847.
34. Davidson MH, Stein EA, Dujovne CA, Hunninghake DB, Weiss SR, Knopp RH, Illingworth DR, Mitchel YB, Melino MR, Zupkis RV, Dubrinska MR, Amin RD, Tobert JA. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997;79:38-42.
35. Frannceschini G, Cassinotti M, Vecchio G, Gianfranceschi G, Pazzucconi F, Murakami T, Sirtori M, D'Acquarica A, Sirtori CR. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb 1994;14:1569-1575.
36. Bredie SJH, De Bruin TWA, Demacker PNM, Kastelein JJP, Stalenhoef AFH. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol 1995;75:348-355.
37. East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med 1988;109:25-32.
38. Da Col PG, Fonda M, Fisicaro M, Tonizzo M, Valenti M, Cattin L. Tolerability and efficacy of combination therapy with simvastatin plus gemfibrozil in type IIb refractory familial combined hyperlipidemia. Curr Ther Res 1993;53:473-483.
39. Athyros VG, Papageorgiou AA, Hagikonstantinou HJ, Papadopoulos GV, Zamboulis CX, Kontopoulos AG. Combined treatment with pravastatin and gemfibrozil in patients with refractory familial combined hyperlipidemia: a clinical study. Drug Invest 1994;7:134-142.
40. Malmandier CL, Lonti JF, Delcroix C, Magat T. Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers. Atherosclerosis 1989;80:101-109.
41. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 1983;80:4124-4128.
42. Goldstein JL, Brown MS. The low density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 1977;46:897-930.
43. Khan B, Wilcox HG, Heimberg M. Cholesterol is required for secretion of very low density lipoprotein by rat liver. Biochem J 1989;258:807-816.
44. Arad Y, Ramakrishnan R, Ginsberg HN. Effects of lovastatin therapy on very-low-density-lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism 1992;41:487-493.
45. Cortner JA, Bennet MJ, Le NA, Coates PM. The effect of lovastatin on very-low-density lipoprotein apolipoprotein B production by the liver in familial combined hyperlipidemia. J Inherit Metab Dis 1993;16:127-134.
46. Parhofer KG, Barret PHR, Dunn J, Schonfeld G. Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia. Clin Invest 1993;71:939-946.
47. Vega GL, Grundy SM. Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidemia. J Intern Med 1991;230:341-349.
48. Chait A, Albers JJ, Brunzell JD. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridemia. Eur J Clin Invest 1980;10:17-22.
49. Janus ED, Nicoli AM, Turner PR, Majili P, Lewis B. Kinetic bases of the primary hyperlipidemias: studies of apolipoprotein B turnover in genetically defined subjects. Eur J Clin Invest 1980;10:161-172.